日本呼吸器学会

日本緩和医療学会

<i>UGT1A1</i> Testing for the Risk of Nanoliposomal Irinotecan-Related Toxicity

Liang, Y; Ando, Y

JOURNAL OF CLINICAL ONCOLOGY   43 巻 ( 3 ) 頁： 357   2025年1月

Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors.

Yasuda T, Ito T, Ishikawa T, Mizuno K, Yamamoto T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Koshiyama Y, Yasuda S, Toyoda H, Ando Y, Shimoyama Y, Kawashima H

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver     2025年1月

Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease

Inukai, Y; Ito, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Shimizu, T; Hattori, M; Takeyama, T; Ando, Y; Nishikawa, T; Morita, K; Toyoda, H; Ishigami, M; Kawashima, H

JOURNAL OF DIGESTIVE DISEASES   25 巻 ( 11-12 ) 頁： 685 - 693   2025年1月

Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team

Ito, T; Mizuno, K; Yamamoto, T; Yasuda, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Hama, M; Kataoka, T; Shimokata, T; Ando, Y; Kawashima, H

HEPATOLOGY RESEARCH   54 巻 ( 11 ) 頁： 1060 - 1069   2024年11月

Greeting from the new editor-in-chief

Ando, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   86 巻 ( 4 ) 頁： 536 - 537   2024年11月

A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy

Liang, Y; Maeda, O; Miyata, K; Tanaka, C; Kanda, M; Shimizu, D; Fukaya, M; Koike, M; Kodera, Y; Ando, Y

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY   20 巻 ( 5 ) 頁： 661 - 667   2024年10月

Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older

Yagishita, S; Yamanaka, Y; Kurata, T; Watanabe, K; Hosomi, Y; Horinouchi, H; Ohe, Y; Nakahara, Y; Naoki, K; Asao, T; Takahashi, K; Saeki, S; Sakagami, T; Nakashima, K; Tsubata, Y; Fujita, Y; Wakui, H; Furuta, M; Konishi, JS; Ohuchi, M; Ando, Y; Mizugaki, H; Hamada, A

CLINICAL PHARMACOLOGY & THERAPEUTICS   116 巻 ( 4 ) 頁： 1042 - 1051   2024年10月

Chemotherapy for metastatic or recurrent soft tissue sarcoma: real-world experience in a single institute

Maeda, O; Shimokata, T; Mitsuma, A; Urakawa, H; Takano, Y; Kondo, C; Furune, S; Miyai, Y; Torii, N; Liang, Y; Morita, S; Inoue, M; Ando, Y

ANNALS OF ONCOLOGY   35 巻   頁： S1349 - S1349   2024年10月

Outcomes of immune-related liver injury managed by hepatologists in a multidisciplinary toxicity team

Ito, T; Mizuno, K; Yamamoto, T; Hama, M; Kataoka, T; Shimokata, T; Kawashima, H; Ando, Y

ANNALS OF ONCOLOGY   35 巻   頁： S1342 - S1343   2024年10月

FEVER AFTER THE ADMINISTRATION OF ATEZOLIZUMAB AND BEVACIZUMAB PREDICTS LIVER INJURY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: A PROSPECTIVE OBSERVATIONAL ANALYSIS USING A MULTIPLEX BEAD-BASED IMMUNOASSAY

Ito, T; Yamamoto, T; Nishida, K; Kobayashi, Y; Mizuno, K; Yokoyama, S; Imai, N; Ishizu, Y; Honda, T; Ishigami, M; Koya, T; Nakashima, S; Naito, T; Yasuda, S; Kuzuya, T; Toyoda, H; Ando, Y; Yoshio, S; Kawashima, H

HEPATOLOGY   80 巻   2024年10月

Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study

Okuji, T; Iwama, S; Kobayashi, T; Yasuda, Y; Ito, M; Yamagami, A; Ando, M; Hase, T; Shibata, H; Hatta, T; Zhou, X; Onoue, T; Kawaguchi, Y; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Ando, Y; Hashimoto, N; Arima, H

NAGOYA JOURNAL OF MEDICAL SCIENCE   86 巻 ( 3 ) 頁： 452 - 463   2024年8月

Effects of <i>KRAS</i>, <i>STK11</i>, <i>KEAP1</i>, and <i>TP53</i> mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma

Liang, Y; Maeda, O; Kondo, C; Nishida, K; Ando, Y

PLOS ONE   19 巻 ( 7 ) 頁： e0307580   2024年7月

Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review.

Kato T, Kawaguchi T, Funakoshi T, Fujiwara Y, Yasuda Y, Ando Y

Cancer diagnosis & prognosis   4 巻 ( 4 ) 頁： 390 - 395   2024年7月

Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring <i>BRAF</i><SUP>V600E</SUP> mutation

Takano, Y; Shimokata, T; Urakawa, H; Kikumori, T; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   13 巻 ( 3 ) 頁： 209 - 213   2024年7月

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

Kobayashi, T; Iwama, S; Yamagami, A; Izuchi, T; Suzuki, K; Otake, K; Yasuda, Y; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Nishio, N; Mori, S; Shimokata, T; Sano, T; Niimi, K; Yoshikawa, N; Akamatsu, S; Ando, Y; Akiyama, M; Sone, M; Ishii, M; Arima, H

CANCER IMMUNOLOGY IMMUNOTHERAPY   73 巻 ( 8 ) 頁： 146   2024年6月

Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review

Ushijima, F; Hase, T; Yamashita, Y; Kim, H; Shimokata, T; Kondo, C; Sato, T; Baba, T; Watanabe, S; Futamura, K; Ando, Y; Mizuno, M; Ishii, M

INTERNATIONAL CANCER CONFERENCE JOURNAL   13 巻 ( 2 ) 頁： 88 - 92   2024年4月

Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review

Kato, T; Kurasawa, S; Takezawa, K; Fujiwara, Y; Yasuda, Y; Ando, Y

ANTICANCER RESEARCH   44 巻 ( 3 ) 頁： 889 - 894   2024年3月

Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer

Liang, Y; Maeda, O; Miyata, K; Kanda, M; Sugita, S; Shimizu, D; Nishida, K; Kodera, Y; Ando, Y

CANCER CHEMOTHERAPY AND PHARMACOLOGY   93 巻 ( 2 ) 頁： 121 - 127   2024年2月

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022 (oct, 10.1007/s10157-023-02415-0, 2022)

Yanagita, M; Muto, S; Nishiyama, H; Ando, Y; Hirata, S; Doi, K; Fujiwara, Y; Hanafusa, N; Hatta, T; Hoshino, J; Ichioka, S; Inoue, T; Ishikura, K; Kato, T; Kitamura, H; Kobayashi, Y; Koizumi, Y; Kondoh, C; Matsubara, T; Matsubara, K; Matsumoto, K; Okuda, Y; Okumura, Y; Sakaida, E; Shibagaki, Y; Shimodaira, H; Takano, N; Uchida, A; Yakushijin, K; Yamamoto, T; Yamamoto, K; Yasuda, Y; Oya, M; Okada, H; Nangaku, M; Kashihara, N

CLINICAL AND EXPERIMENTAL NEPHROLOGY   28 巻 ( 2 ) 頁： 123 - 124   2024年2月

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

Yanagita, M; Muto, S; Nishiyama, H; Ando, Y; Hirata, S; Doi, K; Fujiwara, Y; Hanafusa, N; Hatta, T; Hoshino, J; Ichioka, S; Inoue, T; Ishikura, K; Kato, T; Kitamura, H; Kobayashi, Y; Koizumi, Y; Kondoh, C; Matsubara, T; Matsubara, K; Matsumoto, K; Okuda, Y; Okumura, Y; Sakaida, E; Shibagaki, Y; Shimodaira, H; Takano, N; Uchida, A; Yakushijin, K; Yamamoto, T; Yamamoto, K; Yasuda, Y; Oya, M; Okada, H; Nangaku, M; Kashihara, N

CLINICAL AND EXPERIMENTAL NEPHROLOGY   28 巻 ( 2 ) 頁： 85 - 122   2024年2月

Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer

Nakanishi, K; Tanaka, C; Kanda, M; Miyata, K; Machida, N; Sakai, M; Kobayashi, D; Teramoto, H; Ishiyama, A; Sato, B; Oshima, T; Kajikawa, M; Matsushita, H; Ishigure, K; Yamashita, K; Fujitake, S; Sueoka, S; Asada, T; Shimizu, D; Sugita, S; Kuwatsuka, Y; Maeda, O; Furune, S; Murotani, K; Ando, Y; Ebata, T; Kodera, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   86 巻 ( 1 ) 頁： 43 - 51   2024年2月

Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

Liang, Y; Maeda, O; Ando, Y

JAPANESE JOURNAL OF CLINICAL ONCOLOGY   54 巻 ( 4 ) 頁： 365 - 375   2024年1月

Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer

Maeda, O; Furune, S; Kanda, M; Miyata, K; Shimizu, D; Sugita, S; Nishida, K; Ando, M; Kodera, Y; Ando, Y

CANCER MEDICINE   13 巻 ( 2 ) 頁： e6974   2024年1月

Potential drug interactions between pazopanib and proton pump inhibitors/potassium-competitive acid blockers in patients with soft tissue sarcoma

Liang, Y; Maeda, O; Shimokata, T; Yokota, K; Koike, H; Sakai, T; Ikuta, K; Urakawa, H; Nishida, Y; Akiyama, M; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   13 巻 ( 1 ) 頁： 63 - 67   2024年1月

Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial

Furune, S; Ando, Y

LUNG CANCER   186 巻   頁： 107416   2023年12月

Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA &gt; 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer

Nakanishi, K; Tanaka, C; Kanda, M; Miyata, K; Furukawa, K; Maeda, O; Shimizu, D; Sugita, S; Kakushima, N; Furune, S; Kawashima, H; Ando, Y; Ebata, T; Kodera, Y

CANCERS   15 巻 ( 21 )   2023年11月

Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer

Hatta, T; Hase, T; Hara, T; Kimura, T; Kojima, E; Abe, T; Horio, Y; Goto, Y; Ozawa, N; Yogo, N; Shibata, H; Shimokata, T; Oguri, T; Yamamoto, M; Yanagisawa, K; Ando, M; Ando, Y; Kondo, M; Ishii, M; Hasegawa, Y

CANCER MEDICINE   12 巻 ( 15 ) 頁： 15955 - 15969   2023年8月

Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis

Yamamoto, T; Mizuno, K; Ito, T; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Ishikawa, T; Kanamori, A; Yasuda, S; Toyoda, H; Yokota, K; Hase, T; Nishio, N; Maeda, O; Ishii, M; Sone, M; Ando, Y; Akiyama, M; Ishigami, M; Kawashima, H

INVESTIGATIONAL NEW DRUGS   41 巻 ( 3 ) 頁： 512 - 521   2023年6月

Feasibility assessment of global standard chemoradiotherapy followed by surgery in patients with esophageal cancer

Liang, Y; Maeda, O; Miyata, K; Kanda, M; Shimizu, D; Sugita, S; Okada, T; Ito, J; Kawamura, M; Ishihara, S; Nakatochi, M; Ando, M; Kodera, Y; Ando, Y

MOLECULAR AND CLINICAL ONCOLOGY   18 巻 ( 4 ) 頁： 34   2023年4月

Clustering using unsupervised machine learning to stratify the risk of immune-related liver injury

Yamamoto, T; Morooka, H; Ito, T; Ishigami, M; Mizuno, K; Yokoyama, S; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Yokota, K; Hase, T; Maeda, O; Hashimoto, N; Ando, Y; Akiyama, M; Kawashima, H

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   38 巻 ( 2 ) 頁： 251 - 258   2023年2月

Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study

Maeda, O; Fukaya, M; Koike, M; Miyata, K; Kanda, M; Nishida, K; Ando, M; Kodera, Y; Ando, Y

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY   18 巻 ( 6 ) 頁： 578 - 585   2022年12月

Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment

Maeda, O; Matsuoka, A; Yanagawa, M; Muroyama, Y; Watanabe, K; Liang, Y; Ishikawa, T; Ohno, E; Kawashima, H; Umegaki, H; Kuzuya, M; Ando, Y

JOURNAL OF GERIATRIC ONCOLOGY   13 巻 ( 8 ) 頁： 1260 - 1263   2022年11月

A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

Morita, S; Minami, H; Mitsuma, A; Toyoda, M; Kiyota, N; Ando, Y

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY   18 巻 ( 5 ) 頁： E427 - E434   2022年10月

Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade

Kobayashi, T; Iwama, S; Yamagami, A; Yasuda, Y; Okuji, T; Ito, M; Zhou, X; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Ito, T; Kikumori, T; Inoue, M; Ando, Y; Masuda, N; Kawashima, H; Hashimoto, N; Arima, H

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   107 巻 ( 10 ) 頁： E4115 - E4123   2022年9月

Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association

Yamaguchi, T; Sugiyama, Y; Tanaka, T; Kimura, T; Yumura, Y; Nakano, M; Sugiyama, T; Miura, N; Goya, M; Yamamoto, A; Takahashi, S; Miura, Y; Tsuzuki, T; Masumori, N; Nishiyama, H; Yao, MS; Koie, T; Miyake, H; Saika, T; Saito, S; Akimoto, T; Tamada, T; Ando, Y; Takahashi, S; Suzuki, T; Hinotsu, S; Kamba, T

INTERNATIONAL JOURNAL OF UROLOGY   29 巻 ( 8 ) 頁： 780 - 792   2022年8月

Clinical impact of standardized creatinine on dose adjustment of capecitabine

Ito, A; Ichikawa, K; Miyazaki, M; Sagara, A; Motegi, T; Ando, Y; Senzaki, K; Nagai, T; Yamada, K

NAGOYA JOURNAL OF MEDICAL SCIENCE   84 巻 ( 3 ) 頁： 547 - 553   2022年8月

Direct Observation of Retinal Microvessels in Cancer Patients After Systemic Administration of Bevacizumab and Oxaliplatin.

Mitsuma A, Ito Y, Shimokata T, Tanaka C, Uehara K, Nakayama G, Terasaki H, Ando Y

Cancer diagnosis & prognosis   2 巻 ( 3 ) 頁： 330 - 335   2022年5月

Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline

Iwama, S; Kobayashi, T; Yasuda, Y; Okuji, T; Ito, M; Ando, M; Zhou, X; Yamagami, A; Onoue, T; Kawaguchi, Y; Miyata, T; Sugiyama, M; Takagi, H; Hagiwara, D; Suga, H; Banno, R; Hase, T; Morise, M; Wakahara, K; Yokota, K; Kato, M; Nishio, N; Tanaka, C; Miyata, K; Ogura, A; Ito, T; Sawada, T; Shimokata, T; Niimi, K; Ohka, F; Ishigami, M; Gotoh, M; Hashimoto, N; Saito, R; Kiyoi, H; Kajiyama, H; Ando, Y; Hibi, H; Sone, M; Akiyama, M; Kodera, Y; Arima, H

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   107 巻 ( 4 ) 頁： E1620 - E1630   2022年3月

Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade

Miyai, Y; Sugiyama, D; Hase, T; Asai, N; Taki, T; Nishida, K; Fukui, T; Chen-Yoshikawa, TF; Kobayashi, H; Mii, S; Shiraki, Y; Hasegawa, Y; Nishikawa, H; Ando, Y; Takahashi, M; Enomoto, A

LIFE SCIENCE ALLIANCE   5 巻 ( 6 )   2022年3月

[Chemotherapy for Older Patients with Cancer].

Mitsuma A, Ando Y

Gan to kagaku ryoho. Cancer & chemotherapy   49 巻 ( 1 ) 頁： 13 - 18   2022年1月

Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

Takano, Y; Furune, S; Miyai, Y; Morita, S; Inoue, M; Shimokata, T; Sugishita, M; Mitsuma, A; Maeda, O; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   11 巻 ( 1 ) 頁： 67 - 70   2022年1月

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

Furune, S; Kondo, C; Takano, Y; Shimokata, T; Sugishita, M; Mitsuma, A; Maeda, O; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   11 巻 ( 1 ) 頁： 49 - 49   2022年1月

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

Furune, S; Kondo, C; Takano, Y; Shimokata, T; Sugishita, M; Mitsuma, A; Maeda, O; Ando, Y

INTERNATIONAL CANCER CONFERENCE JOURNAL   11 巻 ( 1 ) 頁： 46 - 48   2022年1月

COVID-19 Pandemic and Trends in Clinical Trials: A Multi-Region and Global Perspective

Nishiwaki, S; Ando, Y

FRONTIERS IN MEDICINE   8 巻   頁： 812370   2021年12月

Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial

Kanda, M; Shimizu, D; Miyata, K; Maeda, O; Tanaka, C; Inokawa, Y; Hattori, N; Hayashi, M; Ando, M; Kuwatsuka, Y; Murotani, K; Nakayama, G; Koike, M; Ando, Y; Ebata, T; Kodera, Y

CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS   24 巻   頁： 100853   2021年12月

A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events

Schöffski, P; Concin, N; Suarez, C; Subbiah, V; Ando, Y; Ruan, SL; Wagner, JP; Mansfield, K; Zhu, X; Origuchi, S; DiDominick, S; Bialucha, CU; Faris, JE; Tran, B

ONCOLOGY RESEARCH AND TREATMENT   44 巻 ( 10 ) 頁： 547 - 556   2021年10月

Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

Ito, T; Ishigami, M; Yamamoto, T; Mizuno, K; Yamamoto, K; Imai, N; Ishizu, Y; Honda, T; Kawashima, H; Yasuda, S; Toyoda, H; Yokota, K; Hase, T; Nishio, N; Maeda, O; Kato, M; Hashimoto, N; Hibi, H; Kodera, Y; Sone, M; Ando, Y; Akiyama, M; Shimoyama, Y; Fujishiro, M

HEPATOLOGY INTERNATIONAL   15 巻 ( 5 ) 頁： 1278 - 1287   2021年10月

Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

Kazama, S; Morimoto, R; Kimura, Y; Shibata, N; Ozaki, R; Araki, T; Mizutani, T; Oishi, H; Arao, Y; Kuwayama, T; Hiraiwa, H; Kondo, T; Furusawa, K; Shimokata, T; Okumura, T; Bando, YK; Ando, Y; Murohara, T

CARDIO-ONCOLOGY   7 巻 ( 1 ) 頁： 26   2021年7月

A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab

Takano, Y; Furune, S; Morita, S; Inoue, M; Shimokata, T; Sugishita, M; Mitsuma, A; Osamu, M; Ando, Y

ANNALS OF ONCOLOGY   32 巻   頁： S354 - S354   2021年7月

Guidelines for clinical evaluation of anti-cancer drugs

Minami, H; Kiyota, N; Kimbara, S; Ando, Y; Shimokata, T; Ohtsu, A; Fuse, N; Kuboki, Y; Shimizu, T; Yamamoto, N; Nishio, K; Kawakami, Y; Nihira, SI; Sase, K; Nonaka, T; Takahashi, H; Komori, Y; Kiyohara, K

CANCER SCIENCE   112 巻 ( 7 ) 頁： 2563 - 2577   2021年7月

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Wick, A; Bähr, O; Schuler, M; Rohrberg, K; Chawla, SP; Janku, F; Schiff, D; Heinemann, V; Narita, Y; Lenz, HJ; Ikeda, M; Ando, Y; Wick, W; Steinbach, JP; Burger, MC; Wenger, K; Lassen, U; Sankhala, KK; Roggia, C; Genvresse, I; Munhoz, C; Rentzsch, C; Reschke, S; Langer, S; Wagner, M; Kaulfuss, S; Cai, C; Lagkadinou, E; Jeffers, M; Peña, C; Tabatabai, G

CLINICAL CANCER RESEARCH   27 巻 ( 10 ) 頁： 2723 - 2733   2021年5月

Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

Minami, H; Doi, T; Toyoda, M; Imamura, Y; Kiyota, N; Mitsuma, A; Shimokata, T; Naito, Y; Matsubara, N; Tajima, T; Tokushige, K; Ishihara, K; Cameron, S; Ando, Y

CANCER SCIENCE   112 巻 ( 2 ) 頁： 725 - 733   2021年2月

Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)

Nakayama, G; Takano, N; Taniguchi, H; Ishigure, K; Yokoyama, H; Teramoto, H; Hashimoto, R; Sakai, M; Ishiyama, A; Kinoshita, T; Hayashi, N; Nakamura, M; Hattori, N; Sato, Y; Umeda, S; Uehara, K; Aiba, T; Sonohara, F; Hayashi, M; Kanda, M; Kobayashi, D; Tanaka, C; Yamada, S; Koike, M; Fujiwara, M; Murotani, K; Ando, M; Ando, Y; Muro, K; Kodera, Y

EUROPEAN JOURNAL OF CANCER   144 巻   頁： 61 - 71   2021年2月

Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study

Tsubata, Y; Shinomiya, S; Inoue, K; Ishikawa, N; Saito, R; Nakashima, K; Hotta, K; Hamada, A; Nagashima, F; Ando, Y; Morita, S; Kobayashi, K; Isobe, T

BMC GERIATRICS   21 巻 ( 1 ) 頁： 74   2021年1月

PhaseIIclinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors

Nishida, Y; Urakawa, H; Nakayama, R; Kobayashi, E; Ozaki, T; Ae, K; Matsumoto, Y; Tsuchiya, H; Goto, T; Hiraga, H; Naka, N; Takahashi, S; Ando, Y; Ando, M; Kuwatsuka, Y; Hamada, S; Ueda, T; Kawai, A

INTERNATIONAL JOURNAL OF CANCER   148 巻 ( 1 ) 頁： 140 - 149   2021年1月

Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial

Nishida, Y; Hamada, S; Urakawa, H; Ikuta, K; Sakai, T; Koike, H; Ito, K; Emoto, R; Ando, Y; Matsui, S

CANCER SCIENCE   111 巻 ( 11 ) 頁： 4187 - 4194   2020年11月

Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5′-Deoxy-5-fluorocytidine, and Creatinine Clearance

Inaishi, T; Fujita, KI; Matsumoto, N; Shimokata, T; Maeda, O; Kikumori, T; Hattori, N; Nakayama, G; Ando, Y

IN VIVO   34 巻 ( 6 ) 頁： 3539 - 3544   2020年11月

Chemotherapy for biliary tract cancer: real-world experience in a single institute

Maeda, O; Ebata, T; Shimokata, T; Matsuoka, A; Inada-Inoue, M; Morita, S; Takano, Y; Urakawa, H; Miyai, Y; Sugishita, M; Mitsuma, A; Ando, M; Mizuno, T; Nagino, M; Ando, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   82 巻 ( 4 ) 頁： 725 - 733   2020年11月

Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

Maeda, O; Ohka, F; Maesawa, S; Matsuoka, A; Shimokata, T; Mitsuma, A; Urakawa, H; Nakamura, S; Shimoyamas, Y; Nakaguro, SM; Wakabayashi, T; Ando, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   82 巻 ( 4 ) 頁： 631 - 644   2020年11月

What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer?

Ogura, A; Uehara, K; Aiba, T; Hattori, N; Nakayama, G; Maeda, O; Ando, Y; Kodera, Y; Ebata, T; Nagino, M

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE   35 巻 ( 11 ) 頁： 2073 - 2080   2020年11月

Gap between pediatric and adult approvals of molecular targeted drugs

Nishiwaki, S; Ando, Y

SCIENTIFIC REPORTS   10 巻 ( 1 ) 頁： 17145   2020年10月

Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer

Minami, H; Ando, Y; Tamura, K; Tajima, T; Isaacs, R

ANTICANCER RESEARCH   40 巻 ( 9 ) 頁： 5229 - 5235   2020年9月

5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter

Maeda, O; Shimokata, T; Ando, Y

CLINICAL CANCER RESEARCH   26 巻 ( 14 ) 頁： 3889 - 3889   2020年7月

Experiences and hidden needs of older patients, their families and their physicians in palliative chemotherapy decision-making: a qualitative study

Tsuboi, R; Sugishita, M; Hirakawa, Y; Ando, Y

JAPANESE JOURNAL OF CLINICAL ONCOLOGY   50 巻 ( 7 ) 頁： 779 - 786   2020年7月

Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

Urakawa, H; Ando, Y; Hase, T; Kikumori, T; Arai, E; Maeda, O; Mitsuma, A; Sugishita, M; Shimokata, T; Ikuta, K; Ishiguro, N; Nishida, Y

INTERNATIONAL JOURNAL OF CANCER   146 巻 ( 12 ) 頁： 3504 - 3515   2020年6月

Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies

Mizuno, K; Ito, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Honda, T; Kawashima, H; Inukai, Y; Toyoda, H; Yokota, K; Hase, T; Maeda, O; Kiyoi, H; Nagino, M; Hibi, H; Kodera, Y; Fujimoto, Y; Sone, M; Gotoh, M; Ando, Y; Akiyama, M; Hasegawa, Y; Fujishiro, M

JOURNAL OF GASTROENTEROLOGY   55 巻 ( 6 ) 頁： 653 - 661   2020年6月

Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.

Nishida, Y; Urakawa, H; Nakayama, R; Ozaki, T; Ae, K; Matsumoto, Y; Ando, Y; Kuwatsuka, Y; Ueda, T; Kawai, A

JOURNAL OF CLINICAL ONCOLOGY   38 巻 ( 15 )   2020年5月

Significance of meflin-positive cancer-associated fibroblasts in predicting response to immune checkpoint inhibitors in non-small cell lung cancer.

Miyai, Y; Enomoto, A; Ando, Y; Takahashi, M

JOURNAL OF CLINICAL ONCOLOGY   38 巻 ( 15 )   2020年5月

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

Okada, N; Iwama, S; Okuji, T; Kobayashi, T; Yasuda, Y; Wada, E; Onoue, T; Goto, M; Sugiyama, M; Tsunekawa, T; Takagi, H; Hagiwara, D; Ito, Y; Suga, H; Banno, R; Hase, T; Morise, M; Kanda, M; Yokota, K; Hashimoto, N; Ando, M; Fujimoto, Y; Nagino, M; Kodera, Y; Fujishiro, M; Hibi, H; Sone, M; Kiyoi, H; Gotoh, M; Ando, Y; Akiyama, M; Hasegawa, Y; Arima, H

BRITISH JOURNAL OF CANCER   122 巻 ( 6 ) 頁： 771 - 777   2020年3月

Detection of bacteria in blood circulation in patients receiving cancer chemotherapy

Ota, A; Morita, S; Matsuoka, A; Shimokata, T; Maeda, O; Mitsuma, A; Yagi, T; Asahara, T; Ando, Y

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   25 巻 ( 1 ) 頁： 210 - 215   2020年1月

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study

Kobayashi, T; Iwama, S; Yasuda, Y; Okada, N; Okuji, T; Ito, M; Onoue, T; Goto, M; Sugiyama, M; Tsunekawa, T; Takagi, H; Hagiwara, D; Ito, Y; Suga, H; Banno, R; Yokota, K; Hase, T; Morise, M; Hashimoto, N; Ando, M; Fujimoto, Y; Hibi, H; Sone, M; Ando, Y; Akiyama, M; Hasegawa, Y; Arima, H

JOURNAL FOR IMMUNOTHERAPY OF CANCER   8 巻 ( 2 )   2020年

Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan.

Nishiwaki S, Ando Y

Journal of global oncology   5 巻   頁： 1 - 3   2019年11月

A longitudinal tracking and quantitative assessment of paclitaxel-induced peripheral neurotoxicity

Matsuoka, A; Mitsuma, A; Maeda, O; Tsunoda, N; Kikumori, T; Ando, Y

ANNALS OF ONCOLOGY   30 巻   2019年10月

Selection of chemotherapy based on geriatric assessment for elderly patients with pancreatic cancer

Maeda, O; Matsuoka, A; Yanagawa, M; Muroyama, Y; Kuzuya, M; Ando, Y

ANNALS OF ONCOLOGY   30 巻   頁： 131 - 131   2019年10月

Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours

Wick, W; Tabatabai, G; Schuler, M; Rorhberg, K; Chawla, SP; Janku, F; Schiff, D; Heinemann, V; Narita, Y; Ando, Y; Lenz, HJ; Ikeda, M; Genvresse, I; Rentzsch, C; Reschke, S; Cyris, C; Cai, C; Jeffers, M; Pena, C; Bähr, O

ANNALS OF ONCOLOGY   30 巻   頁： 170 - +   2019年10月

Recent progress of chemotherapy and biomarkers for gastroesophageal cancer

Maeda, O; Ando, Y

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY   11 巻 ( 7 ) 頁： 518 - 526   2019年7月

Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy.

Maeda O, Matsuoka A, Furukawa K, Miyahara R, Hirooka Y, Ando Y

Molecular and clinical oncology   11 巻 ( 1 ) 頁： 91 - 98   2019年7月

Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of relationship between efficacy and various factors.

Nishida, Y; Sakai, T; Shimizu, K; Urakawa, H; Arai, E; Ikuta, K; Ando, Y; Ishiguro, N

JOURNAL OF CLINICAL ONCOLOGY   37 巻 ( 15 )   2019年5月

Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Wirth, LJ; Leboulleux, S; Kiyota, N; Tahara, M; Muro, K; Ahn, MJ; Ando, Y; Taylor, MH; Takahashi, S; Kim, SB; Misir, S; Dutcus, CE; Xie, R; Joshi, PR; Hughes, BGM; Aller, J; Krzyzanowska, MK; Capdevila, J

JOURNAL OF CLINICAL ONCOLOGY   37 巻 ( 15 )   2019年5月

Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study

Takano, N; Yamada, S; Hirakawa, A; Yokoyama, Y; Kawashima, H; Maeda, O; Okada, T; Ohno, E; Yamaguchi, J; Ishikawa, T; Sonohara, F; Suenaga, M; Takami, H; Hayashi, M; Niwa, Y; Hirooka, Y; Ito, Y; Naganawa, S; Ando, Y; Nagino, M; Goto, H; Fuji, T; Kodera, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   81 巻 ( 2 ) 頁： 233 - 239   2019年5月

Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors

Ando, Y; Iwasa, S; Takahashi, S; Saka, H; Kakizume, T; Natsume, K; Suenaga, N; Quadt, C; Yamada, Y

CANCER SCIENCE   110 巻 ( 3 ) 頁： 1021 - 1031   2019年3月

Modified Docetaxel plus Cisplatin plus Capecitabine (DCX) for Gastric Cancer

Maeda, O; Ando, Y; Matsuoka, A; Furukawa, K; Funasaka, K; Miyahara, R; Hirooka, Y; Goto, H

DIGESTION   99 巻 ( 1 ) 頁： 113 - 113   2019年

Spiritual pain and care needs of elderly cancer patients facing palliative chemotherapy decision-making: Qualitative study.

Tsuboi, R; Sugishita, M; Hirakawa, H; Ando, Y

JOURNAL OF CLINICAL ONCOLOGY   36 巻 ( 34 )   2018年12月

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma

Yonemori, K; Kodaira, M; Satoh, T; Kudo, T; Takahashi, S; Nakano, K; Ando, Y; Shimokata, T; Mori, J; Inoue, K; Oakley, GJ; Sakaguchi, S; Tamura, K

CANCER SCIENCE   109 巻 ( 12 ) 頁： 3962 - 3970   2018年12月

Reporting harms more transparently in trials of cancer drugs

Gyawali, B; Shimokata, T; Honda, K; Ando, Y

BMJ-BRITISH MEDICAL JOURNAL   363 巻   頁： k4383   2018年11月

Cabozantinib in Hepatocellular Carcinoma

Maeda Osamu, Ando Yuichi

NEW ENGLAND JOURNAL OF MEDICINE   379 巻 ( 14 ) 頁： 1384 - 1384   2018年10月

Cabozantinib in Hepatocellular Carcinoma.

Maeda O, Ando Y

The New England journal of medicine   379 巻 ( 14 ) 頁： 1384   2018年10月

A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity

Matsuoka, A; Maeda, O; Mitsuma, A; Uehara, K; Nakayama, G; Nagino, M; Kodera, Y; Ando, Y

ANNALS OF ONCOLOGY   29 巻   2018年10月

Docetaxel, cisplatin and fluorouracil as neoadjuvant chemotherapy for esophageal cancer with prophylactic pegfilgrastim

Maeda, O; Koike, M; Fukaya, M; Miyata, K; Iwata, N; Nagino, M; Kodera, Y; Ando, Y

ANNALS OF ONCOLOGY   29 巻   2018年10月

Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas

Urakawa, H; Nishida, Y; Mitsuma, A; Maeda, O; Sugishita, M; Shimokata, T; Mizutani, T; Arai, E; Ikuta, K; Hamada, S; Ota, T; Ishiguro, N; Ando, Y

ANNALS OF ONCOLOGY   29 巻   2018年10月

Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies

Ando, Y; Doi, T; Mitsuma, A; Mizutani, T; Toyoda, M; Imamura, Y; Kiyota, N; Naito, Y; Matsubara, N; Ishihara, K; Tajima, T; Tokushige, K; Cameron, S; Minami, H

ANNALS OF ONCOLOGY   29 巻   2018年10月

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)

Nakayama, G; Mitsuma, A; Sunagawa, Y; Ishigure, K; Yokoyama, H; Matsui, T; Nakayama, H; Nakata, K; Ishiyama, A; Asada, T; Umeda, S; Ezaka, K; Hattori, N; Takami, H; Kobayashi, D; Tanaka, C; Kanda, M; Yamada, S; Koike, M; Fujiwara, M; Fujii, T; Murotani, K; Ando, Y; Kodera, Y

ONCOLOGIST   23 巻 ( 8 ) 頁： 919 - 927   2018年8月

Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer

Yamada, S; Fujii, T; Yokoyama, Y; Kawashima, H; Maeda, O; Suzuki, K; Okada, T; Ono, E; Yamaguchi, J; Takano, N; Takami, H; Hayashi, M; Niwa, Y; Hirooka, Y; Ito, Y; Naganawa, S; Ando, Y; Nagino, M; Goto, H; Kodera, Y

CANCER CHEMOTHERAPY AND PHARMACOLOGY   81 巻 ( 5 ) 頁： 815 - 821   2018年5月

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.

Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H

Journal of the Endocrine Society   2 巻 ( 3 ) 頁： 241 - 251   2018年3月

Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial 査読有り

Tsukuura, H; Miyazaki, M; Morita, T; Sugishita, M; Kato, H; Murasaki, Y; Gyawali, B; Kubo, Y; Ando, M; Kondo, M; Yamada, K; Hasegawa, Y; Ando, Y

ONCOLOGIST   23 巻 ( 3 ) 頁： 367 - 374   2018年3月

Phase II trial of oral S-1 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard chemotherapies (CCOG-1105 study).

Ezaka, K; Nakayama, G; Yokoyama, H; Matsui, T; Umeda, S; Sunagawa, Y; Murotani, K; Ando, Y; Kodera, Y

JOURNAL OF CLINICAL ONCOLOGY   36 巻 ( 4 )   2018年2月

Randomized phase II trial of CapOX plus bevacizumab versus CapIRI plus bevacizumab as first-line treatment in Japanese patients with metastatic colorectal cancer (CCOG-1201).

Sasahara, M; Nakayama, G; Ishigure, K; Yokoyama, H; Uehara, K; Ishiyama, A; Matsui, T; Nakayama, H; Kobayashi, D; Umeda, S; Sunagawa, Y; Murotani, K; Ando, Y; Kodera, Y

JOURNAL OF CLINICAL ONCOLOGY   36 巻 ( 4 )   2018年2月

Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan 査読有り

Morita, S; Kikumori, T; Tsunoda, N; Inaishi, T; Adachi, Y; Ota, A; Shibata, M; Matsuoka, A; Nakanishi, K; Takeuchi, D; Mizutani, T; Shimokata, T; Hayashi, H; Maeda, O; Ando, Y

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   23 巻 ( 1 ) 頁： 195 - 200   2018年2月

Guidelines for treatment of renal injury during cancer chemotherapy 2016

Horie, S; Oya, M; Nangaku, M; Yasuda, Y; Komatsu, Y; Yanagita, M; Kitagawa, Y; Kuwano, H; Nishiyama, H; Ishioka, C; Takaishi, H; Shimodaira, H; Mogi, A; Ando, Y; Matsumoto, K; Kadowaki, D; Muto, S

CLINICAL AND EXPERIMENTAL NEPHROLOGY   22 巻 ( 1 ) 頁： 210 - 244   2018年2月

Clinical effectiveness of geriatric assessment for predicting the tolerability of outpatient chemotherapy in older adults with cancer 査読有り

Hayashi, N; Matsuoka, A; Goto, H; Gotoh, M; Kiyoi, H; Kodera, Y; Nagino, M; Nagashima, F; Ando, Y

JOURNAL OF GERIATRIC ONCOLOGY   9 巻 ( 1 ) 頁： 84 - 86   2018年1月

Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan

Maeda, O; Yokoyama, Y; Yamaguchi, J; Ota, A; Matsuoka, A; Morita, S; Inoue, M; Mizutani, T; Shimokata, T; Urakawa, H; Mitsuma, A; Nagino, M; Ando, Y

ANNALS OF ONCOLOGY   28 巻   頁： 69 - 69   2017年11月

FDA Approval Summary: Sonidegib-Letter

Gyawali, B; Ando, Y

CLINICAL CANCER RESEARCH   23 巻 ( 19 ) 頁： 5993 - 5993   2017年10月

Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis

Maeda, O; Shimokata, T; Mizutani, T; Inoue, M; Matsuoka, A; Ota, A; Mizuno, T; Ebata, T; Nagino, M; Ando, Y

ANNALS OF ONCOLOGY   28 巻   頁： 50 - 50   2017年10月

Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors

Gyawali, B; Shimokata, T; Ando, Y

ANNALS OF ONCOLOGY   28 巻   2017年9月

A phase 1 study of BYL719, an a-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies

Tomomatsu, J; Iwasa, S; Saka, H; Takahashi, S; Nakano, K; Morita, S; Inoue, M; Nakahama, H; Kogure, Y; Kakizume, T; Natsume, K; Aoki, T; Quadt, C; Yamada, Y; Ando, Y

ANNALS OF ONCOLOGY   28 巻   2017年9月

Erratum: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review.

Yamamoto E, Niimi K, Fujikake K, Nishida T, Murata M, Mitsuma A, Ando Y, Kikkawa F

Molecular and clinical oncology   7 巻 ( 3 ) 頁： 510   2017年9月

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

Nakayama, G; Ishigure, K; Yokoyama, H; Uehara, K; Kojima, H; Ishiyama, A; Hayashi, N; Takano, N; Hattori, N; Kobayashi, D; Tanaka, C; Hayashi, M; Kanda, M; Yamada, S; Sugimoto, H; Koike, M; Fujiwara, M; Fujii, T; Murotani, K; Ando, Y; Kodera, Y

BMC CANCER   17 巻 ( 1 ) 頁： 243   2017年4月

Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

Gyawali, B; Ando, Y

ANNALS OF ONCOLOGY   28 巻 ( 4 ) 頁： 898 - 899   2017年4月

Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer

Honda, K; Takeshita, K; Murotani, K; Mitsuma, A; Hayashi, H; Tsunoda, N; Kikumori, T; Murohara, T; Ando, Y

BREAST CANCER   24 巻 ( 2 ) 頁： 312 - 318   2017年3月

[Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].

Matsuoka A, Ando Y

Gan to kagaku ryoho. Cancer & chemotherapy   44 巻 ( 3 ) 頁： 200 - 203   2017年3月

Modified docetaxel, cisplatin and capecitabine for stage. gastric cancer in Japanese patients: A feasibility study

Maeda, O; Matsuoka, A; Miyahara, R; Funasaka, K; Hirooka, Y; Fukaya, M; Nagino, M; Kodera, Y; Goto, H; Ando, Y

WORLD JOURNAL OF GASTROENTEROLOGY   23 巻 ( 6 ) 頁： 1090 - 1097   2017年2月

Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials

Gyawali, B; Shimokata, T; Ando, M; Honda, K; Ando, Y

ANNALS OF ONCOLOGY   28 巻 ( 2 ) 頁： 246 - 253   2017年2月

Unconvincing Benefit of Combination TherapyWith Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer

Ota, A; Gyawali, B; Matsuoka, A; Ando, Y

JOURNAL OF CLINICAL ONCOLOGY   35 巻 ( 6 ) 頁： 691 - +   2017年2月

[Analysis of Nedaplatin Dose in Patients with Impaired Renal Function].

Araki R, Iwamizu H, Kataoka T, Kumakura Y, Miyazaki M, Nagai T, Ando Y, Yamada K

Gan to kagaku ryoho. Cancer & chemotherapy   44 巻 ( 2 ) 頁： 143 - 147   2017年2月

Carboplatin dosing for adult Japanese patients 招待有り 査読有り

Yuichi Ando, Tomoya Shimokata, Yoshinari Yasuda, and Yoshinori Hasegawa.

Nagoya J Med Sci   76 巻 ( 1 ) 頁： 1-9   2014年2月

A Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. 査読有り

Yuichi Ando, Megumi Inada-inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi.

Cancer Sci   105 巻 ( 3 ) 頁： 347-53   2014年1月

Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. 査読有り

Cancer Sci   101 巻   頁： 2601-5   2010年

UGT1A1*6 and UGT1A1*27 for individualized irinotecan chemotherapy. 招待有り 査読有り

Yuichi Ando, et al.

Curr Opin Mol Ther   9 巻   頁： 258-262   2007年

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis 査読有り

Yuichi Ando, et al.

Cancer Res   60 巻   頁： 6921-6926   2000年

がん関連線維芽細胞の多様性による免疫チェックポイント阻害薬の効果予測の機序解明

研究課題/研究課題番号：20H03528  2020年4月 - 2023年3月

科学研究費助成事業  基盤研究(B)

安藤 雄一, 榎本 篤

がん薬物療法における抗がん薬曝露に対する科学的エビデンスの創出

研究課題/研究課題番号：19K07083  2019年4月 - 2024年3月

科学研究費助成事業  基盤研究(C)

満間 綾子, 安藤 雄一, 下方 智也

バイオ医薬品の有効性・安全性に関わる因子の検討

研究課題/研究課題番号：19K07224  2019年4月 - 2022年3月

科学研究費助成事業  基盤研究(C)

中村 克徳, 益崎 裕章, 安藤 雄一, 松永 民秀, 莚田 泰誠

抗がん薬による下痢・腸炎の病態解明と新治療法の開発

研究課題/研究課題番号：17K08950  2017年4月 - 2020年3月

安藤 雄一

がん薬物療法における血管新生阻害作用に関連した臨床薬理研究

研究課題/研究課題番号：16K08906  2016年4月 - 2020年3月

満間 綾子

抗体医薬リツキシマブ投与によるインフュージョンリアクション発症メカニズムの解明

研究課題/研究課題番号：16K08374  2016年4月 - 2019年3月

中村 克徳

がん悪液質におけるサルコペニア発症機序の解明

研究課題/研究課題番号：15K08906  2015年4月 - 2019年3月

下方 智也

ヒアルロン酸ネットワークと破骨細胞制御による骨転移治療の確立

研究課題/研究課題番号：26462261  2014年4月 - 2018年3月

浦川 浩

がん薬物療法におけるサルコペニアの臨床的意義

研究課題/研究課題番号：26460626  2014年4月 - 2018年3月

安藤 雄一

がん薬物療法における血管新生阻害薬の薬物効果予測因子としての眼底所見の探索的研究

2011年4月 - 2013年3月

科学研究費補助金  基盤研究(C)

がん薬物療法における薬剤誘発性ＱＴ延長の遺伝的要因を含めた患者要因　　　　　　　

2008年4月 - 2011年3月

科学研究費補助金  基盤研究(C)

安藤　雄一